CCL2 and cancer: Figure 4A shows that high MCP‐1 expressing tumours were predominantly early‐stage (Stage I and II; 55.88%) cancers, whereas low MCP‐1 expressing tumours were advanced late‐stage cancers (Stage IV; 57.57%).